Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These findings support the role for the GSTM1 null and the GSTP1 313 AG or GG genotypes in the development of bladder cancer.
|
11757669 |
2001 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Overall, the GSTM1 0/0 genotype conferred a 70% increased risk of bladder cancer (odds ratio [OR] = 1.7; 95% confidence interval [CI] = 1.2-2.5; P = .004).
|
8320745 |
1993 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In the ecological study, age-standardized bladder cancer incidence and frequencies of GSTM1 and GSTT1-null types, estimated prevalence of cigarette smoking, and estimated per capita consumption of cigarettes per adult according to nationality and ethnicity were included.
|
12429337 |
2002 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The overall odds ratio for bladder cancer with the GSTM1 null genotype was 1.4 (95% confidence interval 0.94-2.1), indicating no statistical difference in null genotype frequencies among bladder cancer patients compared to a healthy population.
|
8200072 |
1994 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Smokers lacking the GSTM1 gene are at an approximately 2.4-fold higher risk of bladder cancer (OR = 2.44, C.I.95% = 1.10-5.30).
|
10783912 |
1999 |
Bladder Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
When the OR used to determine statistical power was lowered to 1.2, 2 of the 4 noteworthy associations remained so: GSTM1 null with bladder cancer and acute leukemia.
|
18505952 |
2008 |
Bladder Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
Numerous studies have shown that glutathione S-transferase M1 deficiency (GSTM1*0/0) increases the risk for lung and bladder cancer but the overall risk attributable to GSTM1*0/0 was only around 1.3 according to meta-analyses.
|
10022251 |
1998 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we evaluated dietary intake of ITCs, GSTM1, GSTT1 and NAT2 polymorphisms, and bladder cancer risk in a case-control study.
|
17290402 |
2007 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The GSTM1 null genotype was strongly associated with bladder cancer.
|
10828664 |
2000 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The glutathione S-transferase M1-null genotype also enhanced the risk of bladder cancer among subjects exposed to solvents (OR = 6,5, 95% CI = 2.1-19.7, p = 0.001).
|
24914957 |
2014 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Using data on high-risk occupations for 2258 case patients and 2410 control patients from two bladder cancer studies, we observed that three of 16 known or candidate bladder cancer susceptibility variants displayed statistically significant and consistent evidence of additive interactions; specifically, the GSTM1 deletion polymorphism (P interaction ≤ .001), rs11892031 (UGT1A, P interaction = .01), and rs798766 (TMEM129-TACC3-FGFR3, P interaction = .03).
|
26374428 |
2015 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
An elevated relative bladder cancer risk of GSTM1 null genotype carriers was indicated by comparison of this background with the data of the bladder cancer cases (OR = 1.81; 95% CI [1.10, 2.98]; p = 0.019).
|
9010594 |
1996 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The GSTT1- and GSTM1-null genotypes did not show significant association with tobacco usage in bladder cancer patients.
|
15057507 |
2004 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Thus, common polymorphisms in GSTA1, GSTM1 and GSTT1 are associated with susceptibility to BC in individuals from BEN areas of Serbia.
|
27568660 |
2016 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To estimate the prevalence and importance of GSTT1 and GSTM1 genotypes (implicated in glutathione S-transferase activity) in bladder cancer, to determine whether smoking and occupational factors influence this relationship, and to identify the value of GSTT1 and GSTM1 genotypes as prognostic factors.
|
20942828 |
2011 |
Bladder Neoplasm
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
GSTM1-null and GSTA1-low activity genotypes are associated with enhanced oxidative damage in bladder cancer.
|
23394311 |
2013 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The NAT2 slow genotype, together with GSTM1 null genotype facilitated the development of bladder cancer in almost all ethnic groups.
|
26854433 |
2016 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our data strongly support that high vegetable consumption, especially cruciferous vegetable intake, may protect against bladder cancer and that genetic variants of GSTM1 and NAT2 may modify the association.
|
19549811 |
2009 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
No differences for GSTM1 and GSTP1 genotype prevalence between the bladder cancer cases and the controls were observed, however, the null genotype for the GSTT1 gene and the A/G and G/G variants of the CYP1A1 gene may contribute to the development of bladder cancer.
|
18979064 |
2009 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A greater reduction in bladder cancer risk was observed among current-smokers (OR: 0.43; 95% CI: 0.27-0.71) and carriers of GSTM1-null (homozygous absence) genotypes (OR: 0.43; 95% CI: 0.22-0.85).
|
20732908 |
2010 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We observed non-significant association in null alleles of the GSTM1 (p = 0.611, OR = 1.12, 95% CI = 0.72-1.74 and GSTT1 (p = 0.135, OR = 1.45, 95% CI = 0.89-2.37) with risk of bladder cancer.
|
16005379 |
2005 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We suggest that the CYP1A1 Ile/Ile genotype with GSTM1 null genotype combination may contribute to the development of bladder cancer in this Turkish population.
|
21709011 |
2011 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, we found that NAT2 slow acetylator individuals temporarily carrying wild-type GSTT1 or GSTM1 null genotypes have a strong increased risk of bladder cancer (OR= 26 and 22.17, respectively).
|
19380028 |
2009 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Individual null/low-activity genotypes of GSTM1, GSTT1 and GSTP1 were associated with a 19-48% increase in odds ratio (OR) of bladder cancer.
|
18544563 |
2008 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Previous studies have correlated the absence of the GSTM1 protein with an increased risk of developing some cancers, especially lung or bladder cancer, in heavy smokers.
|
9679567 |
1998 |